Artiva Biotherapeutics, Inc. Research and Development Expense
Artiva Biotherapeutics, Inc. (ARTV) reported Research and Development Expense of $21.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $21.93M, a 22.75% increase year-over-year.
- Artiva Biotherapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $19.31M, a 13.25% increase year-over-year.
- Artiva Biotherapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $16.99M, a 27.61% increase year-over-year.
- Artiva Biotherapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $17.63M, a 30.38% increase year-over-year.
- Artiva Biotherapeutics, Inc. research and development expense for fiscal 2025 was $69.54M, a 38.17% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. research and development expense for fiscal 2024 was $50.33M, a 0.15% increase from fiscal 2023.
- Artiva Biotherapeutics, Inc. research and development expense for fiscal 2023 was $50.25M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.93M 10-Q · filed 2026-08-06 | $41.24M 10-Q · filed 2026-08-06 | $58.23M derived: sum of 3 quarters · filed 2026-08-06 | $75.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $19.31M 10-Q · filed 2026-05-08 | $36.31M derived: sum of 2 quarters · filed 2026-05-08 | $53.94M derived: sum of 3 quarters · filed 2026-05-08 | $71.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $16.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $34.63M derived: sum of 2 quarters · filed 2026-03-10 | $52.49M derived: sum of 3 quarters · filed 2026-08-06 | $69.54M 10-K · filed 2026-03-10 |
| 2025-09-30 | $17.63M 10-Q · filed 2025-11-12 | $35.49M derived: sum of 2 quarters · filed 2026-08-06 | $52.55M 10-Q · filed 2025-11-12 | $65.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.86M 10-Q · filed 2026-08-06 | $34.91M 10-Q · filed 2026-08-06 | $48.23M derived: sum of 3 quarters · filed 2026-08-06 | $61.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $17.05M 10-Q · filed 2026-05-08 | $30.37M derived: sum of 2 quarters · filed 2026-05-08 | $43.89M derived: sum of 3 quarters · filed 2026-05-08 | $56.23M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $13.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $26.84M derived: sum of 2 quarters · filed 2026-03-10 | $39.17M derived: sum of 3 quarters · filed 2026-03-10 | $50.33M 10-K · filed 2026-03-10 |
| 2024-09-30 | $13.52M 10-Q · filed 2025-11-12 | $25.86M derived: sum of 2 quarters · filed 2025-11-12 | $37.01M 10-Q · filed 2025-11-12 | $48.17M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $12.33M 10-Q · filed 2025-08-06 | $23.49M 10-Q · filed 2025-08-06 | $34.64M derived: sum of 3 quarters · filed 2025-08-06 | $47.71M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $11.16M 10-Q · filed 2025-05-08 | $22.31M derived: sum of 2 quarters · filed 2025-05-08 | $35.37M derived: sum of 3 quarters · filed 2025-05-08 | $46.64M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $11.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $24.22M derived: sum of 2 quarters · filed 2025-03-24 | $35.48M derived: sum of 3 quarters · filed 2025-03-24 | $50.25M 10-K · filed 2025-03-24 |
| 2023-09-30 | $13.06M 10-Q · filed 2024-11-12 | $24.33M derived: sum of 2 quarters · filed 2024-11-12 | $39.10M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $11.26M 10-Q · filed 2024-08-29 | $26.03M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |